Clinical Trial · NCT07933887

[68Ga]Ga-SCP PET/CT Imaging in Patients With FAP-Positive Solid Tumors

Overview

This study will evaluate \[68Ga\]Ga-SCP, an investigational radioactive imaging agent, for positron emission tomography/computed tomography (PET/CT) in patients with solid tumors that test positive for fibroblast activation protein (FAP). The main aims are to assess how well \[68Ga\]Ga-SCP PET/CT identifies tumor lesions, evaluate its safety, and estimate the radiation doses received by different organs and the body as a whole. The study will also explore its potential value for early diagnosis.

Sponsor

The First Affiliated Hospital of Soochow University

Phase

Early Phase 1

ClinicalTrials.gov

NCT07933887

Drug / Compound

SCP

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules

Eligibility

Inclusion

Inclusion criteria not yet provided.

Exclusion

  • Brain metastases or uncontrolled underlying medical conditions.Toxicities from prior anticancer treatment that have not resolved to grade 0-1.Active autoimmune disease.Recent participation in another radiopharmaceutical trial.Pregnancy or breastfeeding.